Chronic kidney disease trials recruiting in Alabama

All Chronic kidney disease trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
  NCT06830629 · Phase: Phase 2 · Ages: 18 Years to 68 Years · Sex: All (male and female) · Alabama: Decatur, Huntsville, Montgomery
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Fairhope
• A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
  NCT06173323 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
  NCT06749457 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Alabama: Huntsville
• A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
  NCT06712654 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Huntsville
• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
  NCT07107945 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Huntsville, Montgomery, Sheffield
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Decatur, Huntsville, Montgomery
• Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
  NCT05880537 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Mobile
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Huntsville
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
  NCT06712407 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
  NCT06906640 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
  NCT06906627 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
  NCT07748858 · Phase: Not specified · Ages: 50 Years to 99 Years · Sex: All (male and female) · Alabama: Birmingham
• International (Pediatric) Peritoneal Biobank
  NCT01893710 · Phase: Not specified · Ages: 1 Day to 90 Years · Sex: All (male and female) · Alabama: Birmingham
• Kidney Function in People With Cystic Fibrosis in the Era of HEMT
  NCT06595420 · Phase: Not specified · Ages: 7 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
  NCT06190717 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 84 Years · Sex: All (male and female) · Alabama: Dothan
• Pivotal Study of the Velocity™ pAVF System
  NCT07153939 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Dothan
• Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
  NCT07271186 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Huntsville